lapatinib has been researched along with amsacrine in 1 studies
Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (amsacrine) | Trials (amsacrine) | Recent Studies (post-2010) (amsacrine) |
---|---|---|---|---|---|
1,919 | 305 | 1,442 | 1,293 | 127 | 120 |
Protein | Taxonomy | lapatinib (IC50) | amsacrine (IC50) |
---|---|---|---|
Solute carrier family 22 member 1 | Homo sapiens (human) | 5 | |
Multidrug resistance-associated protein 4 | Homo sapiens (human) | 7.43 | |
DNA topoisomerase 2-alpha | Homo sapiens (human) | 5.47 | |
5-hydroxytryptamine receptor 7 | Cavia porcellus (domestic guinea pig) | 5 | |
DNA topoisomerase 2-beta | Homo sapiens (human) | 1.88 | |
Aldehyde oxidase | Homo sapiens (human) | 3.2 | |
Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 0.2095 | |
Aldehyde oxidase 1 | Rattus norvegicus (Norway rat) | 6.4 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bhosle, J; Hartley, JA; Hochhauser, D; Kiakos, K; Makris, A; Porter, AC; Wu, J | 1 |
1 other study(ies) available for lapatinib and amsacrine
Article | Year |
---|---|
Treatment with gefitinib or lapatinib induces drug resistance through downregulation of topoisomerase IIα expression.
Topics: Amsacrine; Antigens, Neoplasm; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; DNA Breaks, Double-Stranded; DNA Topoisomerases, Type II; DNA-Binding Proteins; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Gefitinib; Gene Expression Regulation, Neoplastic; Histones; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines | 2013 |